SM
Palmeiras vs. Bahia: 6 hrs 33 mins
Upcoming predictions and previews

New England Patriots

Nate Solder had testicular cancer before 2014 season

:Headline: Nate Solder had testicular cancer before 2014 season: ID:218493: from db_amp
New England Patriots offensive lineman Nate Solder admits that he had testicular cancer before the 2014 season which was successfully treated.

New England Patriots offensive lineman Nate Solder has revealed that he had testicular cancer before the 2014 season.

The 27-year-old discovered the problem ahead of his physical before his side's off-season workouts last year and was immediately taken for treatment.

Doctors removed his testicle and determined that the cancer had not spread further, which allowed Solder to feature in all of his side's 19 matches in their Super Bowl-winning campaign.

"I knew nothing about it. It was a complete surprise," Solder told ESPN.

"You Google something like that and it kind of scares you, so I was like, 'I'm not going to freak out about this.' Had I not had a routine physical, I probably wouldn't have checked it, saying, 'Oh, it's just in my head, I'm going to be fine.'

"I was completely healthy, I'm a professional athlete. It can happen to anybody. Make sure you get yourself checked out, especially young men, because that's who it's really targeted toward."

Solder has been with the Patriots since the 2011 season when he was selected in the first round of the Draft by the club.

amp_article__218493 : Database Data restored...  : 
last updated article - 2015-04-23 07:47:10:
html db last update - 2015-04-23 07:47:10 :

ex - 7200 : read : read cache amp html

Click here for more stories about Nate Solder

Click here for more stories about New England Patriots

Share this article now:
Recommended Next on SM


Sports Mole provides in-depth previews and predictions for every match from the biggest leagues and competitions in world football.
AL
Sign up for our FREE daily preview newsletter direct to your inbox!

Loading ...

Failed to load data.



. . . . . . . . . . . . . . .